Sector News

Nestle pushes further into health science with Seres investment

January 7, 2015
Life sciences
(Reuters) – Nestle Health Science has invested $65 million in U.S.-based drugmaker Seres Health Inc, the latest move by its parent company Nestle to diversify away from packaged food.
 
Nestle has been expanding its reach into the fast-growing market for healthcare products that have higher margins than the instant soups, breakfast cereals and coffee the world’s biggest food group is generally known for.
 
The investment will help fund the next stage of development of Seres’ lead product candidate against clostridium difficile infection (CDI) – a bacterial infection of the digestive system – into late-stage clinical trials and help advance its other treatments against infectious, metabolic and inflammatory diseases, Nestle said on Tuesday.
 
Nestle Health Science also said on Tuesday it had entered into a strategic partnership with Seres’ venture capital backer, Flagship Ventures, to support start-ups working on nutritional health and therapy in view of potential further minority direct investments, licensing deals, joint ventures or acquisitions.
 
Nestle set up Nestle Health Science in 2011 to develop new therapeutic approaches for gastrointestinal, metabolic and brain disorders and other health conditions.
 
(Reporting by Silke Koltrowitz; editing by Susan Thomas)

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach